Bayer (FRA:BAYN) received a €125.00 ($154.32) target price from equities research analysts at Jefferies Group in a report issued on Monday, February 26th. The brokerage presently has a “buy” rating on the healthcare company’s stock. Jefferies Group’s price target would suggest a potential upside of 30.74% from the company’s current price.
BAYN has been the topic of a number of other research reports. Sanford C. Bernstein set a €131.00 ($161.73) target price on Bayer and gave the company a “buy” rating in a report on Wednesday, November 29th. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a report on Monday, December 11th. UBS Group set a €125.00 ($154.32) target price on Bayer and gave the company a “buy” rating in a report on Monday, February 12th. Barclays set a €100.00 ($123.46) target price on Bayer and gave the company a “sell” rating in a report on Wednesday, January 3rd. Finally, JPMorgan Chase & Co. set a €125.00 ($154.32) target price on Bayer and gave the company a “buy” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company’s stock. Bayer presently has a consensus rating of “Buy” and an average target price of €119.14 ($147.08).
Shares of Bayer (BAYN) traded down €0.42 ($0.52) during midday trading on Monday, hitting €95.61 ($118.04). The stock had a trading volume of 2,555,956 shares. The firm has a market cap of $79,540.00 and a price-to-earnings ratio of 25.70. Bayer has a fifty-two week low of €91.58 ($113.06) and a fifty-two week high of €123.82 ($152.86).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.